



To,
**Corporate Services Department,
BSE Limited,
P J Towers,1st Floor, Dalal Street,
Fort, Mumbai - 400001.**

**Ref: Eiko Lifesciences Limited
BSE Scrip Code: EIKO 540204**

Dear Sirs,

Subject: Intimation of the meeting of the Rights Issue Committee of Board of Directors of Eiko LifeSciences Limited (“Company”) to be held on Friday, June 30,2023.

Ref.: Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI Listing Regulations”)

This is further to our intimation dated January 31, 2023 informing approval of the Board of Directors of the Company for issuance of the equity shares of the Company of face value of ₹ 10/- each for an amount not exceeding ₹ 25 Crore by way of Rights Issue to the eligible equity shareholders of the Company as on the record date in accordance with the provisions of Companies Act, 2013 and the rules made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, each as amended, and other applicable laws, and pursuant to Regulation 29 of the SEBI Listing Regulations and our intimation of the meeting of the Right Issue Committee of the Board of Directors at their meeting held on Monday, May 15, 2023 to decide, inter alia, the Rights Issue price, rights entitlement ratio and related payment mechanism.

Pursuant to the above referred, we wish to inform you that a meeting of the Right Issue Committee is proposed to be held on Friday, June 30,2023. inter alia, to consider, discuss and decide various matters in connection with the Rights Issue, including the specific terms of the Rights Issue, such as the determination of the record date, timing of the Rights Issue, Other terms of the Rights Issue and to approve letter of offer, the Abridged Letter of Offer, the Application Form and the Right Entitlement Letter to be filed with Securities and Exchange Board of India & BSE Limited.

Further, in terms of SEBI Circular SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, the Company has made necessary arrangement with depositories for the credits of the rights entitlements in dematerialized form in the demat account of the eligible equity shareholders as on the Record Date. The ISIN of such rights entitlement is IN9666Q01014. The rights entitlement of the eligible equity shareholders as on the Record Date, shall be credited prior to the issue opening date, in the respective demat account of the eligible equity shareholders under the afore mentioned ISIN.



EIKO LIFESCIENCES LIMITED

F E E L T H E C H E M I S T R Y

This intimation is issued in terms of the applicable provisions of the SEBI Listing Regulations.

Request you to take the same in your record and disseminate the same.

Thanking you
Your Faithfully,

For Eiko LifeSciences Limited

JAID ISMAIL
KOJAR

Digitally signed by
JAID ISMAIL KOJAR
Date: 2023.06.26
19:16:40 +05'30'

Jaid Ismail Kojar

Chief Financial Officer & Interim Compliance Officer